Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Thera continues to post on cancer on Linkedin

<< Previous

Bullboard Posts

Next >>

Comment by TH1902on Sep 29, 2022 3:15pm

97 Views

Post# 34995668

RE:RE:Thera continues to post on cancer on Linkedin

I keep coming back to Paul's BIG STATEMENT, I agree with JFM, Paul thinks they have proof of concept in cancer...he has the KEY, let's see how many doors it opens...

jfm1330 wrote: They have a message on Linkedin about Paul's participation this morning at the Cantor conference. There is a photo of him and a slide that says: "The receptor is the door to the cancer cell, and we think we have the key". This written as a quote from Levesque with his name and title under it. So it is good to see that in the middle of an open label trial, Paul is willing to make such a fundamental statement. That and saying that they think they have the proof of concept is pretty much the same.